SYGNIS AG enters into collaboration agreement with ECACC for licensing and distribution of Caco-2 cell line
SYGNIS AG enters into collaboration agreement with ECACC for licensing
and distribution of Caco-2 cell line
? Collaboration significantly expands SYGNIS’ Caco-2 business
? SYGNIS already started commercialization of Caco-2 cell line in Europe
Madrid, Spain, and Heidelberg, Germany – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that Navicyte Scientific, part of SYGNIS Group in the US, and the European Collection of Authenticated Cell Cultures (ECACC), part of Public Health England, an agency of the United Kingdom Department of Health have entered into a collaboration agreement for licensing and distributing the Caco-2 cell line to commercial companies. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from SYGNIS in the US and afterwards will provide the Caco-2 materials directly.
“We are very happy about this collaboration agreement with ECACC,” Pilar de la Huerta, Co-CEO

